Laboratory Screening of Lorcaserin for Alcohol Use Disorder

Summary

Heavy-drinking smokers, including those with alcohol use disorder (AUD), are at increased risk for numerous negative health outcomes relative to those who use alcohol or cigarettes only. Although heavy-drinking smokers are recognized as an important subgroup for clinical and public health interventions, there are presently no approved medications for the joint indication of alcohol reduction and smoking cessation. Based on evidence that the serotonin system plays a role in alcohol and nicotine consumption and relapse, this study aims to examine whether a serotonin medication alters alcohol and nicotine responses in smokers with AUD, informing its potential utility as a candidate therapy for this clinical subgroup.

Timeline

Start

2019-10-25

Primary completion

2020-02-26

Completion

2020-02-26

Outcome

Outcome not reported

Stopped: “Medication removed from the U.S. market by the The Food and Drug Administration”

Drugs

Indications